The Journal of Experimental Medicine
IN Cell Analyzer 2000
  Home | Help | Feedback | Subscriptions | Archive | Search | Table of Contents

Published online 1 October 2001. doi:10.1084/jem.194.7.915
This Article
Right arrow Full Text
Right arrow Full Text (PDF, 241K)
Right arrow PPT slides of all figures
Right arrow Alert me when this article is cited
Right arrow Citation Map
Services
Right arrow Email this article
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new content in the JEM
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Yu, H.
Right arrow Articles by Flavell, R. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Yu, H.
Right arrow Articles by Flavell, R. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?
© The Rockefeller University Press, 0022-1007/2001/10/915/ $5.00
The Journal of Experimental Medicine, Volume 194, Number 7, October 1, 2001 915-926


Original Article

Deficiency of Small Gtpase Rac2 Affects T Cell Activation

Hong Yua,b, Dave Leitenberga,b, Baiyong Lia, and Richard A. Flavella,b

a Section of Immunobiology, Yale University School of Medicine, New Haven, CT 06520
b Howard Hughes Medical Institute, Yale University School of Medicine, New Haven, CT 06520
Section of Immunobiology, Yale University School of Medicine, 310 Cedar St., FMB 412, New Haven, CT 06520.203-737-2958203-737-2216

richard.flavell{at}yale.edu

Rac2 is a hematopoietic-specific GTPase acting as a molecular switch to mediate both transcriptional activation and cell morphological changes. We have examined the effect of Rac2 deficiency during T cell activation. In Rac2–/– T cells, proliferation was reduced upon stimulation with either plate-bound anti-CD3 or T cell receptor–specific antigen. This defect is accompanied with decreased activation of mitogen activated protein kinase extracellular signal–regulated kinase (ERK)1/2 and p38, and reduced Ca2+ mobilization. TCR stimulation–induced actin polymerization is also reduced. In addition, anti-CD3 cross-linking–induced T cell capping is reduced compared with wild-type T cells. These results indicate that Rac2 is important in mediating both transcriptional and cytoskeletal changes during T cell activation. The phenotypic similarity of Rac2–/– to Vav–/– cells implicates Rac2 as a downstream mediator of Vav signaling.

Key Words: T cell activation • Rac2 • VAV • MAPK • cytoskeleton


D. Leitenberg's present address is George Washington University, Department of Immunology, Ross Hall Rm. 411, 2300 Eye St. NW, Washington, DC 20037.

B. Li's present address is Pfizer, Inc., East Point Rd., Groton, CT 06340.

Abbreviations used in this paper: ERK, extracellular signal–regulated kinase; JNK, c-Jun NH2-terminal kinase; KO, knockout; MAPK, mitogen-activated protein kinase; SMAC, supramolecular activation cluster; GEF, guanine nucleotide exchange factor.

© 2001 The Rockefeller University Press


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:



  Home | Help | Feedback | Subscriptions | Archive | Search
TABLE OF CONTENTS